Sumitomo Pharma

Press Release

October 30, 2026

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Revision of Its Year-End Dividend Forecast for the Fiscal Year Ending March 31, 2027

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code 4506, Prime Market of TSE; hereinafter the "Company") announced today that it has revised its year-end dividend forecast for the fiscal year ending March 31, 2027, as detailed below. No interim dividend will be paid for the six months ended September 30, 2026.

1. Reasons for the Revision of the Dividend Forecast

Under its policy of prioritizing the restoration of its financial health, as well as growth investments centered on research and development, the Company had announced that its dividend forecast for the fiscal year ending March 31, 2027 was undetermined and would be decided based on future business performance and other factors, given the uncertainties regarding the receipt of sales milestone payments and the outlook for the external environment. Having considered factors such as its performance for the first half of the fiscal year and future business prospects, the Company has decided to resume dividend payments. Accordingly, the Company now forecasts a year-end dividend of 15 yen per share for the fiscal year ending March 31, 2027, marking an expected resumption of dividend payments after paying no dividends for the previous fiscal year.

2. Details of the Revision

	Annual dividend		
	Interim	Year-end	Total
Previous forecast	—	—	—
Revised forecast		15.00 JPY	15.00 JPY
Results for the current term	0.00 JPY		
Results for the previous term (Year ended March 31, 2026)	0.00 JPY	0.00 JPY	0.00 JPY

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the date of this release, which involve both known and unknown risks and uncertainties. Actual results may differ materially from the forecasts and other forward-looking statements contained in this press release due to various factors.

Contact:
Corporate Communications,
Sumitomo Pharma Co., Ltd.
E-mail: prir@sumitomo-pharma.co.jp